Oral Lichen Planus Clinical Trial
Official title:
Evaluation of Salivary Total Oxidant Capacity in Oral Lichen Planus Patients Before and After Treatment With Topical Corticosteroid Supplemented With Vitamin E Versus Topical Corticosteroid Alone
Treatment of oral lichen planus is challenging. Diverse therapeutic modalities have been
suggested, but a permanent cure is not yet available.
In some oral lichen planus patients, topical corticosteroid alone is not sufficiently enough,
thus it may require a supplementation to augment its effect.
This trial will assess the effectiveness of vitamin E as a supplement in management of oral
lichen planus.
The current study is a randomized-controlled clinical trial that follows CONSORT guideline.
The current trial include 30 symptomatic OLP patients in two parallel groups (intervention -
topical triamcinolone acetonide adhesive paste and Vitamin E capsule, control - topical
triamcinolone acetonide adhesive paste and placebo capsule), with allocation ratio 1:1.
Participants were recruited from the pool of the Diagnostic center and the Out-Patient Clinic
of Oral Medicine and Periodontology Department, Faculty of Dentistry, Cairo University, Egypt
between 2016 and 2017.
This clinical trial followed the principles of the Helsinki Declaration and was approved by
the Research ethics committee of Faculty of Dentistry, Cairo University, Egypt (Code: 15733).
Each participant was informed about the details of the study and signed a written consent.
Patients were diagnosed clinically and histopathologically (when required). Inclusion
criteria included erosive and atrophic OLP patients who agreed to take supplied medications.
Exclusion criteria included reticular OLP patients, patients receiving systemic treatment for
OLP during the eight weeks prior to the study, patients receiving topical medications for OLP
during the four weeks prior to the study, patients suffering from systemic disease; pregnant
ladies and lactating ladies.
Interventions:
The intervention was 0.1% triamcinolone acetonide adhesive paste (Kenacort A Orabase -
Dermapharm) and 400 mg Vitamin E capsule (Vitamin E 400 - Pharopharmaceuticles) for the
experimental group and 0.1% triamcinolone acetonide adhesive paste (Kenacort A Orabase -
Dermapharm) and identical placebo capsule for the control group.
Patients were instructed to apply triamcinolone acetonide regularly four times a day after
meals and before sleeping for four weeks and to refrain eating and drinking for 30 minutes
after the application. In addition, patients were asked to take one capsule (Vitamin E or
placebo) once daily at morning.
Outcomes:
Pain intensity was evaluated using numerical rating scale (NRS) at baseline, daily during the
first week, then weekly for four weeks. NRS ranges from 0 to 10, with 0 indicating "no pain"
and 10 indicating "pain as bad as you can imagine".21 Clinical improvement of the oral
lesions was scored using Thongprasom et al. scale at baseline and weekly for four weeks. In
Thongprasom et al. scale, lesions are given score as follows: 0, no lesions, normal mucosa;
1, Mild white striae, no erythematous area; 2, White striae with atrophic area < 1 cm2; 3,
White striae with atrophic area > 1 cm2; 4, White striae with erosive area < 1 cm2 and 5,
White striae with erosive area > 1 cm2.22 Salivary level of TAC was evaluated using ELISA
kit. Unstimulated whole saliva samples were used for determination of TAC using ImAnOx
(TAS/TAC) Kit provided by Immun Diagnostik, Germany. Participants were asked to refrain
eating, drinking or using saliva stimulators for one hour before sample collection.
Participants were asked to swallow, then tilt their head forward and expectorate saliva into
a centrifuge tubes for 5 minutes without swallowing. The saliva samples were frozen at -70°C,
until analysis. The saliva samples were centrifuged at 4500 g for 15 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Not yet recruiting |
NCT06428630 -
Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus
|
Early Phase 1 | |
Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
Withdrawn |
NCT03836885 -
Apremilast - Oral Lichen Planus Trial
|
Phase 2 | |
Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 |